Kidney Disease: Clinical Trials

21 trials for Kidney Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 2 active not recruiting, 2 recruiting, 2 withdrawn. 21 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 121Completed 15, Active not recruiting 2, Recruiting 2, Withdrawn 2
Phase 23Completed 3

Follow Kidney Disease: new trials by email Literature Review of Kidney Disease trials Research Report on Kidney Disease

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive
GSK4771261, Placebo - Kidney Disease
Phase 1RecruitingGlaxoSmithKline302026-05-182026-10-05
Adia Med of Winter Park LLC Chronic Kidney Disease Research Study
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione IV, Glutathione Spray - Chronic Kidney Disease, Kidney Disease
Phase 1RecruitingAdia Med of Winter Park LLC1002026-05-182026-06-17
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
LY3841136 - Kidney Disease, Renal Insufficiency Chronic
Phase 1Active not recruitingEli Lilly and Company282026-02-242026-08-19
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
GSK4771261, Placebo matching GSK4771261 - Kidney Disease
Phase 1Active not recruitingGlaxoSmithKline862024-12-112026-07-30
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
Mezagitamab - Kidney Disease, Glomerulonephritis
Phase 1CompletedTakeda172022-08-162026-06-01
Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects
Nitazoxanide - Renal Impairment, Renal Disease
Phase 1CompletedGenfit772022-04-252022-10-28
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
N-acetyl D-mannosamine - Kidney Disease
Phase 1CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)102016-07-072023-02-24
A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.
Sativex - Renal Insufficiency, Kidney Disease
Phase 1WithdrawnGW Pharmaceuticals Ltd2016-01-012016-08-11
Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )
darTreg infusion - Kidney Disease
Phase 1CompletedUniversity of California, San Francisco62015-04-012018-10-15
PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
IDN-6556 - Renal Impairment, Renal Insufficiency
Phase 1CompletedConatus Pharmaceuticals Inc.162014-01-012016-01-28
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
PINTA 745, Placebo - End Stage Renal Disease, Kidney Disease
Phase 1 / Phase 2CompletedPinta Biotherapeutics512014-01-012018-04-11
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
AMG 386 + Paclitaxel, AMG 386 - Advanced Solid Tumors, Kidney Disease
Phase 1CompletedAmgen352011-09-192017-11-06
Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction
TRV120027, Normal Saline - Heart Failure, Kidney Disease
Phase 1CompletedTrevena Inc.172011-08-012012-08-27
Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers
Propranolol, Losartan, Eprosartan - Kidney Disease
Phase 1CompletedUniversity of California, San Francisco242010-03-012013-05-30
Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment
GSK1278863A, Placebo - Kidney Disease
Phase 1CompletedGlaxoSmithKline122009-08-122017-07-27
Repeat Dose Safety Study for Compound to Treat Anemia
1278863, Placebo - Kidney Disease
Phase 1CompletedGlaxoSmithKline242009-03-132017-06-22
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
Alemtuzumab, Mycophenolate mofetil, Sirolimus - Kidney Transplantation, Kidney Disease
Phase 1 / Phase 2CompletedUniversity of Miami92004-09-012012-10-02
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
Alemtuzumab, Sirolimus, Tacrolimus - Kidney Transplantation, Kidney Disease
Phase 1 / Phase 2CompletedUniversity of Wisconsin, Madison102003-11-012018-06-29
MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery
MRI - Renal Artery Obstruction, Kidney Disease
Phase 1CompletedNational Heart, Lung, and Blood Institute (NHLBI)602001-12-012008-03-04
Oxaliplatin in Cancer Patients With Impaired Kidney Function
Oxaliplatin - Kidney Disease, Neoplasm
Phase 1CompletedNational Cancer Institute (NCI)601999-09-012008-03-04

Showing 20 of 21. Sign in to see all of them.

Narrower conditions

Kidney Diseases (21)  ·  Renal Insufficiency (8)  ·  Kidney Failure, Chronic (3)  ·  Renal Insufficiency, Chronic (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Atherosclerosis (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Embolism, Cholesterol (1)  ·  Glomerulonephritis (1)  ·  HIV Infections (1)  ·  Heart Failure (1)  ·  Hypertension, Renovascular (1)  ·  Kidney Neoplasms (1)  ·  Marijuana Abuse (1)  ·  Neoplasm Metastasis (1)

Broader conditions

Female Urogenital Diseases (21)  ·  Female Urogenital Diseases and Pregnancy Complications (21)  ·  Male Urogenital Diseases (21)  ·  Urogenital Diseases (21)  ·  Urologic Diseases (21)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Pathologic Processes (5)  ·  Chronic Disease (4)  ·  Disease Attributes (4)  ·  Cardiovascular Diseases (2)  ·  Immune System Diseases (2)  ·  Renal Insufficiency (2)  ·  Renal Insufficiency, Chronic (2)  ·  Abnormalities, Multiple (1)  ·  Arterial Occlusive Diseases (1)

Interventions

Alemtuzumab (2)  ·  Kidney Transplantation (2)  ·  Sirolimus (2)  ·  Tacrolimus (2)  ·  3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1)  ·  Acetaminophen (1)  ·  Acyclovir (1)  ·  Clotrimazole (1)  ·  Diphenhydramine (1)  ·  Hydrochlorothiazide (1)  ·  Losartan (1)  ·  Methylprednisolone (1)  ·  Mycophenolic Acid (1)  ·  N-acetylmannosamine (1)  ·  Nystatin (1)

Sponsors

GlaxoSmithKline (4)  ·  University of California, San Francisco (2)  ·  Adia Med of Winter Park LLC (1)  ·  Amgen (1)  ·  Conatus Pharmaceuticals Inc. (1)  ·  Eli Lilly and Company (1)  ·  GW Pharmaceuticals Ltd (1)  ·  Genfit (1)  ·  National Cancer Institute (NCI) (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Pinta Biotherapeutics (1)  ·  Takeda (1)  ·  Trevena Inc. (1)

Countries

United States (17)  ·  Australia (2)  ·  Netherlands (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Canada (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Italy (1)  ·  Japan (1)  ·  New Zealand (1)  ·  Singapore (1)

Top investigators

A. D'jamali, MD, MS (1)  ·  Carol Addy, MD (1)  ·  Christopher Haqq, MD, PhD (1)  ·  Dave Hagerty, MD (1)  ·  George W. Burke, III, MD (1)  ·  Jeffrey B Kopp, M.D. (1)  ·  Leslie Z Benet, PhD (1)  ·  Lynda Frassetto, MD (1)  ·  Richard Edwards, DO (1)  ·  Sang-Mo Kang, M.D. (1)  ·  Tartaglione TA (1)

Results publications

PMID 13278189, PMID 23903014, PMID 32446407, PMID 40444214, PMID 40465397, PMID 41630898

NIH funding

2014 (1), 2025 (1)